Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=18 Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Castrate-resistant Prostate Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths — 11; 7; 7; 4 participants
Phase 3 N=38 Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation
Inflammation · Macrophage Infiltration · Cardiovascular Disease
Primary: Inflammatory Biomarker 1: Plasma hsCRP Concentration — 3.4; 5.4; 2.9; 7.4 mg/L — p=0.006
Phase 3 N=351 A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Multiple Myeloma
Primary: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) — 52.1; 20.1 weeks — p=<0.001
Phase 3 N=2,249 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Meningococcal Disease
Primary: Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination — 81; 82; 100; 100 Percentages of…
Phase 3 N=40 Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
HIV Infections
Primary: Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve. — 0.0066; 0.0070 1/h — p=0.43
Phase 3 N=284 A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013) — 88.3; 75.8 percentage of participants
Phase 3 N=125 Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With Posttraumatic Stress Disorder
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale, for DSM-IV (CAPS IV) — -15.97; -11.22 units on a scale — p=> .05
Phase 3 N=1,015 A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
Chronic Kidney Disease
Primary: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported. — 172; 183 participants
Phase 3 N=3,445 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Cardiovascular Diseases · Heart Diseases · Heart Failure, Congestive
Primary: Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First — 6.6; 5.9 Events…
Phase 3 N=1,020 A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
Chronic Kidney Disease
Primary: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported. — 178; 177 participants
Phase 3 N=104 The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Disorder of Urinary Stent
Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale
Phase 3 N=558 HALT Progression of Polycystic Kidney Disease Study A
Kidney, Polycystic
Primary: Study A: Percent Annual Change in Total Kidney Volume — 6.0; 6.2; 5.6; 6.6 percentage of Total Kidney Volume — p=0.52
Phase 3 N=488 Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Kaplan-Meier Estimates for Overall Survival — 10.4; 6.5 months — p=0.0829
Phase 3 N=51 An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Related AEs, Discontinuation Due to AEs, or Death — 78.4; 5.9; 15.2; 7.8 percentage of…